



Press release

SCG Cell Therapy expands global R&D by opening a research innovation site at the IZB in Germany

The Innovation and Start-up Center Biotechnology (IZB) is thus home to another biotech company conducting research in the field of immunotherapy

SINGAPORE/MUNICH, January 20, 2022 – Singapore-based SCG Cell Therapy Pte. Ltd. (“SCG”) has opened a new R&D site in the Innovation and Start-up Center Biotechnology in Martinsried/Munich in Germany to accelerate SCG’s development of new immunotherapeutic candidates. The mission of the site is to expand the company’s portfolio of innovative products and platforms in the field of immunotherapy. The new R&D center in the Munich area focuses on the discovery and validation of new immunotherapeutic targets, generation of novel cell therapies and the development of related technologies.

Together with other sites in Singapore and China, SCG will be able to offer comprehensive solutions from research and discovery to regulatory and clinical development, marketing and commercialization. “We are excited to be opening a new research hub for SCG which contributes to completing our cell therapy pipeline ranging from T-cell receptor discovery to GMP-grade vector, TCR-T and CAR-T cell production,” says Dr. Karin Wisskirchen, Managing Director and Head of Research of SCG Germany.

“Internal and external innovation are an integral part of our growth strategy and opening a research facility in Germany will boost our international R&D network particularly in Europe. It will also open up opportunities for SCG to attract top talent to join our mission to identify novel new cell therapies for patients and our pipeline,” Dr. Greg Fanning an experienced international pharma expert and acting CEO of SCG Germany added.

SCG stands for Singapore, China, Germany with each location having a significant place in SCG’s foundation. Opening an additional site in Germany underlines company’s strategic expansion at locations known for innovation in this field and facilitate the entry into global markets for the company clinical stage pipeline.

SCG Cell Therapy GmbH will be located in Planegg/Martinsried at the “Innovation and Start-up Center Biotechnology” (IZB), a leading center for biotechnology in Europe. Founded in 1995, IZB has grown to become one of the world’s top 10 biotechnology hubs and has produced a large number of successful businesses. The location provides the ideal infrastructure for biotech startups to transform their products or services into successful business propositions, within a competence cluster for life science ventures. Spanning across 26,000 m², IZB is home to over 50 biotech companies.

“We are glad to have established SCG Cell Therapy within Germany’s biotech hotspot, which will facilitate collaborations with strong academic and biotech partners in Munich”, says Prof. Dr. Ulrike Protzer, Director of the Institute of Virology of the Technical University of Munich and the Helmholtz Center Munich, and Scientific Founder of SCG. SCG’s founding technology originates from intensive research in Munich, and maintains strong links through collaborations.



Sharing his thoughts on SCG's establishment in IZB, Dr. Peter Hanns Zobel, Managing Director of IZB said, "We are overjoyed to be able to support such a motivated biotech company. SCG's pipeline and international network make success tangible".

About SCG Cell Therapy:

SCG is a rapidly evolving biotechnology company focusing on the development of novel immunotherapies for patients with infections and infection-associated cancer. Established and headquartered in Singapore, SCG has a strong footprint and scientific network in Singapore, China and Germany. The company develops T cell therapies, bispecific antibodies, and therapeutic vaccines for hepatitis B, helicobacter pylori and human papillomavirus infection and associated malignancies, which attribute to high burden of diseases worldwide. SCG's scientific founder is Prof. Dr. Ulrike Protzer, a leading virologist and director of the Institute of Virology of the Technical University of Munich and of the Institute of Virology of the Helmholtz Center Munich.

Contact:

SCG Cell Therapy Pte Ltd
50 Raffles Place
#37-00 Singapore Land Tower
Singapore 048623

phone + 65 6829 7180

fax + 65 6829 7070

info@scgcell.com // www.scgcell.com

SCG Cell Therapy GmbH

Am Klopferspitz 19

81252 Planegg

phone +49 89 7007 6625

info.de@scgcell.com // www.scgcell.com

Disclaimer:

This press release may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, SCG Cell Therapy Pte Ltd does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. SCG Cell Therapy assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated.

About Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich

The IZB was founded in 1995 and is located in Planegg-Martinsried and Freising-Weihenstephan, and has developed into a leading biotechnology center in Europe. More than 50 biotech companies with over 700 employees are currently located on 26,000 m² of land. Here, work focuses on the development of drugs against the most serious diseases, such as cancer, Alzheimer's and various



autoimmune diseases. A key criterion for the success of the IZBs is their close proximity to top-level research at both the Martinsried/Grosshadern campus and the Weihenstephan campus. The new infrastructure measures such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the Elhardt Chemistry College, the two kindergartens Bio Kids and Bio Kids², as well as the two restaurants SEVEN AND MORE and Café Freshmaker are also location factors that are highly appreciated by the company founders. Successful companies that have emerged from the IZB include Medigene AG, MorphoSys AG, Micromet GmbH (today Amgen AG), Octopharma GmbH, Corimmun (today Janssen-Cilag), Rigontec GmbH (today MSD), ibidi GmbH, Coriolis GmbH and Immunic Therapeutics. More information at www.izb-online.de

Press contact and image requests:

Susanne Simon, Head of Public Relations

Fördergesellschaft IZB mbH, Am Klopferspitz 19, D-82152 Planegg Martinsried

Phone: +49 (0)89/55 279 48-17,

E-mail: simon@izb-online.de:

Website: www.izb-online.de